17:02 EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDA
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom receives warning letter from FDA, sees no impact to FY25 guidance
- Dexcom’s Strong Market Position and Growth Potential Drive Buy Rating and Price Target Increase
- DexCom price target raised to $104 from $101 at Citi
- DexCom put volume heavy and directionally bearish
- Altimmune appoints Teri Lawver, Jerry Durso to board